asia pacific medtech forum diabetes

GlycoLeap at Asia Pacific Medtech Forum 2016

We are proud of being part of the Innovation Showcase at Asia Pacific Medtech Forum 2016. This forum is a way to share and access new innovations, and create new partnerships in health care. We were there to present GlycoLeap, our flagship product for people living with type 2 diabetes.

Presentation- Asia Pacific Medtech Forum

As part of the showcase, our CEO and Founder, Mr  Nawal Roy, addressed the growing size of the diabetes population in Singapore. He shared insights from our current user stories on how GlycoLeap nudged people with type 2 diabetes towards sustainable changes for better health. His inspiring talk drew in the crowds and generated a lot of interest at our showcase stand.

Nawal Roy speaking at Asia Pacific medtech forum

Showcase- Asia Pacific Medtech Forum

Showcasing GlycoLeap was an exciting opportunity to spread the word about our program. We met people from all over the world, working in all different areas of health and technology. From interns, to lecturers, to MOH, to media, to healthcare professionals- they were interested to know more about our GlycoLeap. We even had some people sign up for themselves or family members!

GlycoLeap showcase Asia Pacific Medtech Forum 2016

Exciting new startups

The innovation showcase gave us the opportunity to see what else is happening in healthcare start ups locally. Some of the new exciting products included a smart infusion system for delivery of pain relief in child birth, and a new app which helps people to track and identify triggers for migraines. In addition there were talks and showcases for larger companies such as BD and Medtronic too.

All in all it’s an exciting and valuable opportunity for us to share the news about GlycoLeap- A smart coach for people with type 2 diabetes.

7 thoughts on “GlycoLeap at Asia Pacific Medtech Forum 2016

  1. Pingback: olumiant price usa
  2. Pingback: baricitinib moa
  3. Pingback: buy aralen uk
  4. Pingback: lumigan 01

Comments are closed.